早期乳腺癌循环肿瘤DNA:综述
本综述总结早期乳腺癌中循环肿瘤DNA(ctDNA)检测微小残留病(MRD)的现有数据。ctDNA在新辅助治疗中的动态与病理完全缓解及长期结局相关,治疗结束后ctDNA阳性与未来远处复发强相关;但ctDNA指导管理能否改善结局证据有限,最佳检测时机与频率未知,需前瞻性干预试验验证临床实用性。
要点
- 新辅助治疗期间ctDNA动态与病理完全缓解及长期结局相关。
- 根治性治疗后ctDNA阳性(MRD)与未来远处复发强相关。
- ctDNA指导治疗能否改善结局证据有限,需前瞻性试验验证。
核心结论
- ctDNA-based MRD assays有助细化风险分层、早期发现复发并辅助治疗决策,但临床实用性尚未证实。
研究设计与样本
- 本综述汇总早期乳腺癌中ctDNA MRD检测的当前数据。
主要发现
- ctDNA在新辅助治疗中的动态与病理完全缓解及长期结局相关。
- 根治性治疗后ctDNA阳性(如存在MRD)与未来远处复发强相关。
- 监测期间ctDNA出现先于转移性疾病的临床诊断。
- 观察性研究和荟萃分析支持ctDNA作为现有风险分层工具的补充生物标志物。
临床怎么用
- 临床医生在将ctDNA检测纳入患者照护前,应理解其优势、局限性、不断发展的证据基础以及患者偏好。
局限性
- ctDNA指导管理改善结局的证据有限。
- 最佳检测时机和频率仍未知。
- 缺乏检测方法间比较的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Circulating tumor DNA (ctDNA) has emerged as a noninvasive biomarker with the potential to detect minimal residual disease (MRD), monitor treatment response, and identify recurrence (eg, molecular relapse) earlier than conventional clinical or imaging approaches. Although ctDNA-based MRD assays have demonstrated prognostic value in early breast cancer, their optimal clinical utility remains uncertain. OBSERVATIONS: This review summarizes the current data on ctDNA MRD assays in early breast cancer. Although these assays have established analytical and clinical validity, their clinical utility remains uncertain. Dynamics of ctDNA during neoadjuvant therapy are associated with pathologic complete response and long-term outcomes. Following completion of curative-intent therapy, ctDNA positivity (eg, presence of MRD) is strongly associated with future distant recurrence. Similarly, the emergence of ctDNA during surveillance precedes the clinical diagnosis of overt metastatic disease. Although observational studies and meta-analyses have supported ctDNA as a complementary biomarker for established risk-stratification tools, evidence that demonstrates improved outcomes with ctDNA-guided management remains limited. Furthermore, the optimal timing and frequency of testing remain unknown, and studies comparing assays are lacking. Multiple ongoing prospective interventional trials are evaluating whether ctDNA-guided treatment escalation or de-escalation can improve patient outcomes and support the routine implementation of ctDNA assays in clinical practice. CONCLUSIONS AND RELEVANCE: ctDNA-based MRD assays hold promise for refining risk stratification, enabling earlier detection of recurrence, and informing treatment decisions in patients with early breast cancer, but clinical utility has not yet been demonstrated. Prospective trials are essential to determine whether ctDNA-guided interventions improve outcomes beyond standard management. Clinicians should understand the strengths, limitations, and evolving evidence base of ctDNA assays, as well as patient preferences, prior to incorporating them into patient care.
引用
- Schlam I, Tolaney SM, Lin NU, et al. Circulating Tumor DNA in Early Breast Cancer: A Review. JAMA Oncol. 2026. PMID: 42207534. doi:10.1001/jamaoncol.2026.1465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。